Melinta Therapeutics (MLNT) Stock Price, News & Analysis

Company Overview

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.35 to $0.50
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 713,628 shs
• Market Capitalization: $6.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MLNT Stock Analysis - Frequently Asked Questions

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics Inc (NASDAQ:MLNT) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share for the quarter, missing analysts' consensus estimates of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%.

When did Melinta Therapeutics' stock split?

Shares of Melinta Therapeutics reverse split on the morning of Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Melinta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 11/12/2019
• Today: 11/02/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MLNT
• CUSIP: 15130J10
• CIK: 1461993
• Web: www.melinta.com
• Phone: 908-617-1309
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($17.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-157,190,000.00
• Net Margins: -393.39%
• Pretax Margin: N/A
• Return on Equity: -101.29%
• Return on Assets: -28.68%

Debt

• Debt-to-Equity Ratio: 1.11
• Current Ratio: 1.03
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $96.43 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.96 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 13,750,000
• Free Float: N/A
• Market Cap: $6.88 million
• Optionable: Optionable
• Beta: 4.16